×
S&P 500   3,812.37 (+0.71%)
DOW   31,015.69 (+0.78%)
QQQ   281.38 (+0.39%)
AAPL   138.19 (+1.08%)
MSFT   258.25 (+0.55%)
META   159.11 (-1.33%)
GOOGL   2,157.42 (-1.00%)
AMZN   109.22 (+2.83%)
TSLA   673.82 (+0.06%)
NVDA   145.78 (-3.83%)
NIO   21.15 (-2.62%)
BABA   115.76 (+1.83%)
AMD   73.91 (-3.35%)
MU   53.76 (-2.75%)
CGC   2.88 (+1.05%)
T   21.37 (+1.96%)
GE   63.87 (+0.31%)
F   11.26 (+1.17%)
DIS   95.91 (+1.60%)
AMC   13.59 (+0.30%)
PFE   52.13 (-0.57%)
PYPL   71.18 (+1.92%)
NFLX   178.45 (+2.05%)
S&P 500   3,812.37 (+0.71%)
DOW   31,015.69 (+0.78%)
QQQ   281.38 (+0.39%)
AAPL   138.19 (+1.08%)
MSFT   258.25 (+0.55%)
META   159.11 (-1.33%)
GOOGL   2,157.42 (-1.00%)
AMZN   109.22 (+2.83%)
TSLA   673.82 (+0.06%)
NVDA   145.78 (-3.83%)
NIO   21.15 (-2.62%)
BABA   115.76 (+1.83%)
AMD   73.91 (-3.35%)
MU   53.76 (-2.75%)
CGC   2.88 (+1.05%)
T   21.37 (+1.96%)
GE   63.87 (+0.31%)
F   11.26 (+1.17%)
DIS   95.91 (+1.60%)
AMC   13.59 (+0.30%)
PFE   52.13 (-0.57%)
PYPL   71.18 (+1.92%)
NFLX   178.45 (+2.05%)
S&P 500   3,812.37 (+0.71%)
DOW   31,015.69 (+0.78%)
QQQ   281.38 (+0.39%)
AAPL   138.19 (+1.08%)
MSFT   258.25 (+0.55%)
META   159.11 (-1.33%)
GOOGL   2,157.42 (-1.00%)
AMZN   109.22 (+2.83%)
TSLA   673.82 (+0.06%)
NVDA   145.78 (-3.83%)
NIO   21.15 (-2.62%)
BABA   115.76 (+1.83%)
AMD   73.91 (-3.35%)
MU   53.76 (-2.75%)
CGC   2.88 (+1.05%)
T   21.37 (+1.96%)
GE   63.87 (+0.31%)
F   11.26 (+1.17%)
DIS   95.91 (+1.60%)
AMC   13.59 (+0.30%)
PFE   52.13 (-0.57%)
PYPL   71.18 (+1.92%)
NFLX   178.45 (+2.05%)
S&P 500   3,812.37 (+0.71%)
DOW   31,015.69 (+0.78%)
QQQ   281.38 (+0.39%)
AAPL   138.19 (+1.08%)
MSFT   258.25 (+0.55%)
META   159.11 (-1.33%)
GOOGL   2,157.42 (-1.00%)
AMZN   109.22 (+2.83%)
TSLA   673.82 (+0.06%)
NVDA   145.78 (-3.83%)
NIO   21.15 (-2.62%)
BABA   115.76 (+1.83%)
AMD   73.91 (-3.35%)
MU   53.76 (-2.75%)
CGC   2.88 (+1.05%)
T   21.37 (+1.96%)
GE   63.87 (+0.31%)
F   11.26 (+1.17%)
DIS   95.91 (+1.60%)
AMC   13.59 (+0.30%)
PFE   52.13 (-0.57%)
PYPL   71.18 (+1.92%)
NFLX   178.45 (+2.05%)
NASDAQ:ALRN

Aileron Therapeutics Stock Forecast, Price & News

$0.24
-0.02 (-7.69%)
(As of 07/1/2022 01:54 PM ET)
Add
Compare
Today's Range
$0.23
$0.25
50-Day Range
$0.26
$0.54
52-Week Range
$0.32
$1.34
Volume
57,379 shs
Average Volume
318,405 shs
Market Capitalization
$21.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00
30 days | 90 days | 365 days | Advanced Chart

Receive ALRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aileron Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALRN Stock Forecast (MarketRank)

Overall MarketRank

1.67 out of 5 stars

Medical Sector

948th out of 1,429 stocks

Pharmaceutical Preparations Industry

472nd out of 682 stocks

Analyst Opinion: 3.3Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
Aileron Therapeutics logo

About Aileron Therapeutics (NASDAQ:ALRN)

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.

ALRN Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALRN
Fax
N/A
Employees
9
Year Founded
N/A

Company Calendar

Last Earnings
5/05/2022
Today
7/01/2022
Next Earnings (Estimated)
8/10/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+1,150.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.66666666666667
Research Coverage
3 Analysts

Profitability

Net Income
$-26.16 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.48 per share

Miscellaneous

Free Float
88,281,000
Market Cap
$21.80 million
Optionable
Not Optionable
Beta
2.50














Aileron Therapeutics Frequently Asked Questions

Should I buy or sell Aileron Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aileron Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Aileron Therapeutics stock.
View analyst ratings for Aileron Therapeutics
or view top-rated stocks.

What is Aileron Therapeutics' stock price forecast for 2022?

3 brokerages have issued 1-year price targets for Aileron Therapeutics' stock. Their ALRN stock forecasts range from $1.00 to $5.00. On average, they expect Aileron Therapeutics' share price to reach $3.00 in the next year. This suggests a possible upside of 1,150.0% from the stock's current price.
View analysts' price targets for Aileron Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Aileron Therapeutics' stock price performed in 2022?

Aileron Therapeutics' stock was trading at $0.5629 on January 1st, 2022. Since then, ALRN shares have decreased by 57.4% and is now trading at $0.24.
View the best growth stocks for 2022 here
.

When is Aileron Therapeutics' next earnings date?

Aileron Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for Aileron Therapeutics
.

How were Aileron Therapeutics' earnings last quarter?

Aileron Therapeutics, Inc. (NASDAQ:ALRN) announced its earnings results on Thursday, May, 5th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.01.
View Aileron Therapeutics' earnings history
.

Who are Aileron Therapeutics' key executives?

Aileron Therapeutics' management team includes the following people:
  • Dr. Manuel C. Aivado, Pres, CEO & Director (Age 52, Pay $912.38k)
  • Dr. Vojislav Vukovic M.D., Ph.D., Sr. VP & Chief Medical Officer (Age 55, Pay $574.22k)
  • Dr. D. Allen Annis Ph.D., Sr. VP of Research (Age 49)

What other stocks do shareholders of Aileron Therapeutics own?

When did Aileron Therapeutics IPO?

(ALRN) raised $61 million in an IPO on Thursday, June 29th 2017. The company issued 3,800,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

What is Aileron Therapeutics' stock symbol?

Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN."

How do I buy shares of Aileron Therapeutics?

Shares of ALRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aileron Therapeutics' stock price today?

One share of ALRN stock can currently be purchased for approximately $0.24.

How much money does Aileron Therapeutics make?

Aileron Therapeutics (NASDAQ:ALRN) has a market capitalization of $21.80 million. The company earns $-26.16 million in net income (profit) each year or ($0.300010) on an earnings per share basis.

How many employees does Aileron Therapeutics have?

Aileron Therapeutics employs 9 workers across the globe.

How can I contact Aileron Therapeutics?

Aileron Therapeutics' mailing address is 490 Arsenal Way, Watertown MA, 02472. The official website for Aileron Therapeutics is www.aileronrx.com. The company can be reached via phone at (617) 995-0900 or via email at [email protected].

This page (NASDAQ:ALRN) was last updated on 7/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.